Injexate (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to produce tetrahydrofolate. This halts synthesis of purine and pyrimidine nucleotides, reducing DNA, RNA and protein formation. The resulting antiproliferative effect limits growth of rapidly dividing immune cells and cancer cells, while also dampening inflammatory cytokine production.

The dose of Injexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Dosage regimens can vary widely, and the prescriber determines the appropriate amount and frequency.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated during pregnancy and should be stopped well before conception. Use while breastfeeding is also discouraged, as the drug can be excreted in milk and affect the infant.

To request Injexate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Injexate (methotrexate) is a conventional synthetic DMARD that is generally less expensive than biologic agents such as TNF‑α inhibitors. It can be administered subcutaneously, offering more predictable absorption than oral forms. While biologics target specific cytokines, methotrexate provides broad immunosuppression and is often used as first‑line therapy.

Injexate should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Injexate is given by subcutaneous injection, typically into the abdomen or thigh. The injection should be performed using aseptic technique with a suitable needle, and the site should be rotated to minimize local irritation. Administration is usually performed by a healthcare professional or a trained patient.

The most critical adverse events include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, and pulmonary fibrosis or interstitial pneumonitis. Patients should be monitored regularly for liver enzymes, blood counts and respiratory symptoms, and the drug should be discontinued if serious toxicity is identified.

Injexate is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic disease, significant renal impairment, or existing bone‑marrow failure. Caution is also advised for patients with active infections or immunodeficiency.